Study of Breast Cancer Patients to Improve Treatment and Care Using Molecular Testing and Health Research in Early and Advanced Stages
Led by University Hospital Tuebingen · Updated on 2026-01-30
13500
Participants Needed
61
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying patients with breast cancer, focusing on those with metastatic disease who typically have the poorest outlook. The trial aims to improve treatment decisions and quality of care by analyzing tumor characteristics. Although national guidelines recommend molecular reassessment of metastatic tumors, biopsies are rare due to invasiveness, so the study explores blood-based methods to assess tumor features and their relation to treatment outcomes and health economics.
The study involves two groups about 3,500 patients with locally advanced or metastatic breast cancer receiving any line of treatment, and approximately 10,000 patients with early breast cancer undergoing neoadjuvant or adjuvant therapy regardless of regimen. Blood samples will be collected during routine blood draws to analyze tumor molecular characteristics and biomarkers for progression and survival.
Participants will be followed with assessments including quality of life, therapy adherence, depression factors, and adverse events at study entry and regularly up to 60 months. The study will measure progression-free survival in metastatic breast cancer and disease-free survival in early breast cancer, along with overall survival and health economic outcomes. Results of molecular testing will be shared with patients at study end, providing comprehensive data to support improved breast cancer care.
CONDITIONS
Brief Title
Praegnant Breast Cancer: Early/Advanced/Metastatic
Research Team
E
Erik Belleville, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Adult breast cancer patients aged 18 years or older
Patients with breast cancer and no distant metastases diagnosed within 91 days before study entry (early breast cancer group)
Patients with invasive breast cancer aged 18 years or older (advanced/metastatic group)
Patients with metastatic or locally advanced, inoperable breast cancer confirmed by clinical imaging
Patients willing and able to sign the informed consent form
You will not qualify if you...
Patients who did not sign the informed consent form
Patients not eligible for observation due to lack of availability or severe comorbidities as judged by the treating physician
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Monitoring
Duration - Up to 60 months
Participants with breast cancer are observed over time with blood samples taken during routine blood draws to assess disease progression, therapy adherence, quality of life, and other health factors.
Visits every 3 months or following a change in therapy until Month 24; every 6 months from Month 24 until death or withdrawal of consent
Long-term Monitoring
Duration - Until study completion at 2030-07
Participants continue to be observed after the initial monitoring period for survival outcomes and receipt of molecular testing results.
1 visit at study end for molecular test results
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Observational Study of Cardiac Effects in Women Receiving Systemic Therapy for Early-Stage Breast Cancer
Study of Dalpiciclib Combined With Anti-HER2 and Endocrine Therapy as First-Line Maintenance for Women With Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer
Cryoablation Treatment for Early Luminal Breast Cancer in Postmenopausal Women
Evaluating Megestrol Acetate Plus Trastuzumab Deruxtecan for Fatigue in Advanced Breast Cancer Patients
Study of Breast Cancer Patients to Improve Treatment and Care Using Molecular Testing and Health Research in Early and Advanced Stages
Evaluation of Endopredict Genomic Test in Early HR-positive, HER2-negative Breast Cancer
A 10-year Study on Risk and Treatment Decisions
Evaluating Omission of Hormone Therapy in Postmenopausal Women with Small, Low-Risk HRHER2- Early Breast Cancer
Validation Study of Oncoliq Blood Test for Early Breast Cancer Detection in Women Aged 40 to 70
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry.
Volkmar Müller, Alexander Hein, Andreas D Hartkopf...